Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism
Autore:
Lera, G; Zirulnik, J;
Indirizzi:
Juan A Fernandez Hosp, Neurol Unit, Buenos Aires, DF, Argentina Juan A Fernandez Hosp Buenos Aires DF Argentina nos Aires, DF, Argentina Juan A Fernandez Hosp, Infectol Unit, Buenos Aires, DF, Argentina Juan A Fernandez Hosp Buenos Aires DF Argentina nos Aires, DF, Argentina
Titolo Testata:
MOVEMENT DISORDERS
fascicolo: 1, volume: 14, anno: 1999,
pagine: 128 - 131
SICI:
0885-3185(199901)14:1<128:PSWCIP>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
AIDS ENCEPHALOPATHY; MOVEMENT-DISORDERS; DISEASE; CHLORPROMAZINE; INFECTION; TREMOR;
Keywords:
clozapine; HIV-associated psychosis; AIDS; secondary parkinsonism; antipsychotic agents; extrapyramidal symptoms;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Lera, G Juncal 2160,3, RA-1125 Buenos Aires, DF, Argentina Juncal 2160,3 Buenos Aires DF Argentina RA-1125 es, DF, Argentina
Citazione:
G. Lera e J. Zirulnik, "Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism", MOVEMENT D, 14(1), 1999, pp. 128-131

Abstract

Clozapine (CZP) is an atypical antipsychotic drug that does not appear to block striatal dopamine receptors. In six patients who met the criteria of HIV-associated psychosis and who had previously developed moderate parkinsonism as a result of the use of typical neuroleptic agents, CZP was added inan open, rising dose study. Subjects were evaluated at baseline after at least 7 days without neuroleptic drugs and then monthly for 3 months of the experimental treatment using three rating scales: Brief Psychiatric Rating Scare (BPRS), Clinical Global Impression (CGI), and motor examination of the Unified Parkinson's Disease Rating Scale (UPDRS). A significant reductionin psychopathology as represented in the BPRS total score (54.2 at baseline versus 23.9 at month 3) and CGI (2 and 8, respectively) was obtained witha mean CZP dose of 27.08 mg/day. Parkinsonism also improved by an average of 76.5% at the end of the study. One patient did not complete the study asa result of a progressive decrease in leukocyte count while on CZP. These preliminary results suggest that the pharmacologic properties of CZP may beof value in the management of HIV-psychotic patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 01:02:51